QC
SAGE

Quent Capital’s Sage Therapeutics SAGE Stock Holding History

Quent Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21
Closed -$1K – 1357
2022
Q3 		$1K Hold
21
– – ﹤0.01% 1174
2022
Q2 		$1K Hold
21
– – ﹤0.01% 1125
2022
Q1 		$1K Hold
21
– – ﹤0.01% 1216
2021
Q4 		$1K Buy
+21
New +$879 ﹤0.01% 1053

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Quent Capital's SAGE Position: Q4 2022 in Review

Quent Capital sold out of Sage Therapeutics (SAGE) in Q4 2022, closing a stake of 21 shares — an estimated $1K sold.

Quent Capital first reported a position in SAGE in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q3 2022. 206 funds tracked by Wall St. Rank hold SAGE as of Q4 2022.

  • Quent Capital reported no remaining Sage Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Quent Capital sold 21 Sage Therapeutics shares in Q4 2022, an estimated $1K.
  • Quent Capital first reported a position in Sage Therapeutics in Q4 2021 and held it in 4 quarters.
  • Quent Capital's Sage Therapeutics position peaked at $1K in Q3 2022.
  • 206 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2022.

Based on Quent Capital's 13F filing for Q4 2022, filed 19 Jan 2023.